Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 100.0%, from $151.00M to $0.00. Over 3 years (FY 2021 to FY 2024), Acquisitions shows an upward trend with a 145.9% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $37.75M | $37.75M | $37.75M | $0.00 | $933.00M | $0.00 | $0.00 | $1.06B | -$3.00M | -$29.00M | $544.00M | $1.85B | -$7.00M | $151.00M | $249.00M | $1.00M | $0.00 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | -100.0% | — | -100.0% | — | — | -100.3% | -866.7% | >999% | +240.3% | -100.4% | >999% | +64.9% | -99.6% | -100.0% | — |
| YoY Change | — | — | — | — | >999% | -100.0% | -100.0% | — | -100.3% | — | — | +75.3% | -133.3% | +620.7% | -54.2% | -99.9% | +100.0% | -100.0% |